TrialNature medicine2024

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

Iris Nederlof et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.